Arkolith/Insider Trading/SNDX/Form 4

Goldan Keith A.

Chief Financial OfficerSyndax Pharmaceuticals Inc (SNDX) · full profile →Form 4 · filed Feb 9, 2024
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
5
4 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 7, 2024Grant(A)12K—$051K
Feb 7, 2024Grant(A)35K—$040K
Jan 31, 2024Other(J)1K$17.42$21K5K
Jul 31, 2023Other(J)862$18.12$16K3K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 7, 2024Grant(A)70K$22.28$1.6M70K

Transaction Codes

A
Grant / award
J
Other acquisition / disposition

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001562180-24-001222) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML